AC Immune
Yahoo Finance • 10 months ago
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
AC Immune SA AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company’s strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunotherapy now considered to be the optimal app... Full story
Yahoo Finance • last year
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
AC Immune to Present at the Jefferies 2023 London Healthcare Conference Lausanne, Switzerland, November 7, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative... Full story
Yahoo Finance • last year
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE Phase 1b/2 study on track for H1 2024AC... Full story
Yahoo Finance • last year
We're Not Very Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, y... Full story
Yahoo Finance • last year
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023 Lausanne, Switzerland, November 02, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmac... Full story
Yahoo Finance • last year
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
PRESSRELEASE AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic ACI-125891 delivers the first element of a precision medicine approac... Full story
Yahoo Finance • last year
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative d... Full story
Yahoo Finance • last year
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenera... Full story
Yahoo Finance • last year
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
AC Immuneto Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland,September 05,2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision m... Full story
Yahoo Finance • last year
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
AC ImmuneShowcasingPrecision Medicine Programsat AAIC 2023 Lausanne, Switzerland,July3,2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today anno... Full story
Yahoo Finance • last year
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
AC ImmuneReceives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy,ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE study enrolling well and expanding to sites in USA with Investigational New Drug (IN... Full story
Yahoo Finance • last year
AC Immune Holds Annual General Meeting of Shareholders
AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical com... Full story
Yahoo Finance • 2 years ago
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
AC Immuneat AD/PD™ 2023to PresentNew Clinical and Preclinical Data fromits Precision Medicine Pipeline Ten presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM)AC Immune’s Chief Medical Officer to p... Full story
Yahoo Finance • 2 years ago
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
AC ImmuneReports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important mil... Full story
Yahoo Finance • 2 years ago
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
AC Immuneto Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 Lausanne, Switzerland,March8,2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine f... Full story
Yahoo Finance • 2 years ago
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
AC ImmuneAwarded New Grants from MJFF and TargetALS Supporting Programs Targeting TDP-43 The Michael J. Fox Foundation grant supports the development of AC Immune’s first-in-class TDP-43 PET tracer programTarget ALS Foundation grant suppo... Full story
Yahoo Finance • 2 years ago
AC Immune to Present at the SVB Securities Global Biopharma Conference
AC Immune to Present at the SVB Securities Global Biopharma Conference Lausanne, Switzerland,February 2,2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative dis... Full story
Yahoo Finance • 2 years ago
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial ACI-24.060 elicited an anti-Abeta antibody response in ABATE’s first, low dose cohortACI-2... Full story
Yahoo Finance • 2 years ago
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
AC ImmunePartner Life Molecular Imaging Initiates Phase 3Study of TauPETDiagnostic PI-2620for Alzheimer’s Disease First Alzheimer’s patient imaged with PI-2620 in ADvance, the pivotal Phase 3 trialPI-2620 potentially best-in-class Tau PET... Full story
Yahoo Finance • 2 years ago
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
AC Immune’sAlzheimer’s Disease Vaccine-candidate ACI-35.030 Selected forFurther Development Data presented at CTAD 2022 confirm excellent clinical performance of ACI-35.030 vaccine candidateBased on this new clinical data, ACI-35.030 has... Full story
